Epigenomics and Radiopharmaceuticals in Preoperative Chemoradiotherapy: Advancing Personalized Cancer Treatment Protocols

<b><i>Introduction:</i></b> Cancer remains a major global health burden, with treatment outcomes often impacted by tumor heterogeneity and individual patient factors. Personalized cancer therapies are increasingly essential to improve prognosis and response. <b><i>Methods:</i></b> This study explores the integration of epigenomics and radiopharmaceuticals into preoperative chemoradiotherapy as a strategy to personalize cancer treatment. Epigenomic profiling identifies reversible heritable changes in gene expression, revealing tumor biology and therapy resistance mechanisms. Radiopharmaceuticals, which combine radioactive isotopes with tumor-specific ligands, enable targeted radiation delivery. <b><i>Results:</i></b> The combined use of epigenetic markers and radiopharmaceuticals allows for tailoring chemoradiotherapy regimens, enhancing tumor selectivity, and minimizing off-target effects. Early clinical data show improved therapeutic efficacy, tumor downstaging, higher survival rates, and reduced recurrence. Epigenetic therapies, including DNA methylation and histone deacetylase inhibitors, further sensitize tumors to radiopharmaceuticals, enhancing treatment synergy. <b><i>Conclusions:</i></b> Integrating epigenomics and radiopharmaceuticals into preoperative chemoradiotherapy represents a significant advancement toward personalized oncology. This approach enhances treatment precision and effectiveness while reducing toxicity. Continued research and clinical validation are critical to transitioning this dual strategy into routine practice.